CLL11

Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukaemia.

See the Homepage of the GCLLSG for further information (publicly available) and protocol (password protected).

Therapies for relapsed/refractory CLL

CLL2P

A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemia

See the Homepage of the GCLLSG for further information (publicly available) and protocol (password protected).

Transplantation Studies

Currently no recruiting transplantation trials.

Trials for T-PLL

T-PLL2

Phase II Trial of Combined Immunochemotherapy with Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients with Previously Treated or Untreated T-Prolymphocytic Leukemia.

See the Homepage of the GCLLSG for further information (publicly available) and protocol (password protected).